MARKET

PRTC

PRTC

PURETECH HEALTH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.85
+1.85
+5.14%
Closed 16:00 01/27 EST
OPEN
36.86
PREV CLOSE
36.00
HIGH
38.70
LOW
33.95
VOLUME
9.94K
TURNOVER
--
52 WEEK HIGH
65.90
52 WEEK LOW
33.95
MARKET CAP
1.09B
P/E (TTM)
-5.5933
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 6d ago
Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today
PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has 
Benzinga · 01/14 10:37
PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar
BOSTON, January 14, 2022--PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Under the Ticker Symbol "GLS"
Business Wire · 01/14 07:00
Wall Street Analysts Predict an 82% Upside in PureTech Health PLC Sponsored ADR (PRTC): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 81.5% in PureTech Health PLC Sponsored ADR (PRTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate ...
Zacks · 01/11 15:00
PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference
BOSTON, January 07, 2022--PureTech Founder and CEO, Daphne Zohar, to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30am EST
Business Wire · 01/07 12:00
BRIEF-Puretech Health's LYT-100 Achieves Reduction In Healthy Older Adults Experiencing GI-Related Events
reuters.com · 01/06 08:54
PureTech’s LYT-100 achieves 50% reduction in GI-related adverse events vs. pirfenidone
PureTech Health (NASDAQ:PRTC) announces results from a double-blind crossover study in healthy older adults demonstrating that ~50% fewer subjects treated with PureTech’s LYT-100 (deupirfenidone) experienced gastrointestinal (GI)-related adverse events (AE...
Seekingalpha · 01/06 08:12
Insiders who bought PureTech Health plc (LON:PRTC) stock in the last 12 months recover some losses, but still down US$21k
Insiders who purchased US$260k worth of PureTech Health plc ( LON:PRTC ) shares over the past year recouped some of...
Simply Wall St. · 12/31/2021 11:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTC. Analyze the recent business situations of PURETECH HEALTH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRTC stock price target is 70.67 with a high estimate of 72.00 and a low estimate of 70.00.
High72.00
Average70.67
Low70.00
Current 37.85
EPS
Actual
Estimate
-0.523.968.4412.92
2019/12
2020/06
2020/12
2021/06
2021/12
Institutional Holdings
Institutions: 4
Institutional Holdings: 82.81K
% Owned: 0.29%
Shares Outstanding: 28.78M
TypeInstitutionsShares
Increased
0
0
New
2
52.79K
Decreased
1
43
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.70%
Pharmaceuticals & Medical Research
+0.35%
Key Executives
Non-Executive Chairman
Christopher Viehbacher
President/Executive Director
Bharatt Chowrira
Chief Executive Officer/Co-Founder/Director
Daphne Zohar
Co-Founder/Non-Executive Director
Robert Langer
Chief Financial Officer
George Farmer
Corporate Executive
Joep Muijrers
Chief Scientific Officer
Joseph Bolen
Other
Eric Elenko
Other
Julie Krop
Director
Alison Bauerlein
Director
Matthew Patterson
Director
Jane Wildman
Non-Executive Independent Director
Raju Kucherlapati
Non-Executive Independent Director
John Lamattina
Non-Executive Independent Director
Kiran Mazumdar-Shaw
Non-Executive Independent Director
Marjorie Scardino
No Data
About PRTC
PureTech Health PLC is a clinical stage biotherapeutics company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The Company's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

Webull offers kinds of PureTech Health PLC (ADR) stock information, including NASDAQ:PRTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTC stock methods without spending real money on the virtual paper trading platform.